Alzheimer's

Health advisors have unanimously backed the much-anticipated drug Leqembi. After receiving conditional approval in January, early results demonstrated Leqembi's efficacy in early-stage ofAlzheimer's disease. The FDA is currently reviewing more conclusive data to determine if the drug justifies full approval with final decision by July 6. Furthermore, with this, the new drug is likely to be introduced in market, for people in summers.